Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Completed 19Terminated 8Unknown 7Recruiting 6Withdrawn 3Not yet recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3UNKNOWN 1OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 49Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 17Fallopian Tube Neoplasms 17Esophageal Squamous Cell Carcinoma 15Esophageal Neoplasms 15Neoplasms 14Neoplasm Metastasis 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Uterine Cervical Neoplasms 12Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Colorectal Neoplasms 6Carcinoma 6Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Peritoneal Neoplasms 3

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Paclitaxel × Clear all
NCT07423078 2026-04-13

WOLF

University of Pittsburgh

Phase 2 Recruiting
87 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

University of Pittsburgh

Phase 2 Recruiting
15 enrolled

Recurrence

NCT06670911 2025-02-24

ACCESS-I

Instituto Nacional de Cancer, Brazil

Phase 2 Recruiting
44 enrolled

Recurrence

NCT04921527 2024-10-18

CHIPRO

Chipscreen Biosciences, Ltd.

Phase 3 Recruiting
454 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University

Phase 2 Recruiting
40 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03731442 2018-12-12

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

ChineseAMS

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡